Endoscopy activity and cancer detection was slower to recover in gastric cancers, such as colorectal cancer (CRC), after the COVID-19 pandemic, with cancer detection slower than endoscopy activity to recover, […]
The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. This time, the agency is considering limiting these immunotherapies’ use in stomach cancer and esophageal […]
Abstract: Microsatellite instability (MSI) has been widely acknowledged as an important factor regulating tumor intrinsic biological behavior and affecting the survival of gastric cancer patients. Here, we firstly identified the […]
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD […]
The recent application of targeted and immuno-oncology drugs to treat gastric cancer has significantly changed the outcome of inoperable gastric cancer. In the past, conventional chemotherapy for gastric cancer consisted […]
Gastric cancer, a significant global health challenge, is characterized by a complex transition from inflammation-induced premalignant lesions to malignancy. The quest for early diagnosis and prevention is impeded by the […]
AstraZeneca and Daiichi Sankyo‘s antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received conditional approval from the China National Medical Products Administration (NMPA) for gastric cancer. The approval allows Enhertu […]
(Reuters) -Britain’s health regulator said on Wednesday it has approved Japan-based Astellas Pharma’s therapy to treat a type of gastric cancer. The monoclonal antibody, which can attach itself to certain […]
The Association for Clinical Oncology (ASCO) is applauding the Senate Appropriations Committee for its bipartisan support of federal cancer research in the fiscal year (FY) 2025 Labor, Health and Human […]
Treatment with EO-3021 (SYSA1801) produced promising preliminary data in a small cohort of patients with advanced, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) cancers expressing Claudin 18.2 (CLDN18.2), according […]
